89bio Inc (ETNB) - News Archive

89bio Inc. Fortifies Strategic Growth with Inducement Grants and Public Offering Initiatives89bio, Inc. a clinical-stage biopharmaceutical company, is making significant strides in strengthening its workforce and financ...

89bio s Strategic Moves: Inducement Grants and Public Offering ImplicationsIn an ambitious stride towards reinforcing its workforce and fortifying its financial leeway, 89bio, Inc. (Nasdaq: ETNB) announced on February 6...

89bio, Inc. Launches $250 Million Public Stock Offering Amid Surge in Share PriceSAN FRANCISCO January 27, 2025 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical firm dedicated to innovating therapies for l...

89bio Inc.: Strategic Moves Amidst Financial Challenges and Promising Clinical DevelopmentsOverview of Recent Developments 89bio Inc. has been capturing attention in the biotechnology sector as it navigates a challengin...

89bio, Inc. Boosts Workforce with Strategic Inducement Grants Amid Market GrowthIn a significant move reflecting its commitment to attracting top talent, 89bio, Inc. (Nasdaq: ETNB) announced the approval of a non-qualif...

In a strategic move designed to bolster its workforce and align incentives, 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in innovative therapies for liver and cardiometabolic disea...

San Francisco, CA – November 12, 2024 – In a strategic move to bolster its financial standing, clinical-stage biopharmaceutical company 89bio, Inc. (Nasdaq: ETNB) has announced the pricing of an upsized public offering...

89bio Expands Workforce with Inducement Grants Under Nasdaq Rules to Enhance R&D and Commercial Efforts SAN FRANCISCO, Oct. 11, 2024 89bio, Inc. (Nasdaq: ETNB), a prominent clinical-stage biopharmaceutical company, is m...

On September 19, 2024, 89bio, Inc. made a significant announcement regarding its commitment to strengthening its workforce amid its ambitious mission to combat liver and cardiometabolic diseases. The clinical-stage biop...

SAN FRANCISCO - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease treatments, has recently made significant strides in its growth as it continues to...

89bio, Inc. Grants Stock Options to New Employees as Strategic Investment in Liver and Cardiometabolic TherapiesIn a recent press release, 89bio, Inc. (Nasdaq: ETNB) announced the approval of non-qualified stock options...

SAN FRANCISCO, June 14, 2024 - Clinical-stage biopharmaceutical company, 89bio, Inc. (NASDAQ: ETNB), has recently made a significant move towards expanding its operations and treatment options for liver and cardiometabo...

89bio Presents 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress 89bio, a clinical-stage biopharmaceutical company, has...

The latest in clinical trial development comes to the forefront as 89bio Inc., a premier clinical-stage biopharmaceutical company, recently initiated the Phase 3 ENLIGHTEN-Cirrhosis study of pegozafermin. This trial is...

89bio Announces Additional Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Amid Share Price DeclineIn a recent press release, 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liv...

In a recent press release, 89bio, Inc. (Nasdaq: ETNB), a leading clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease treatment, announced inducement grants under Nasdaq Listing Rul...

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a progressive liver disease characterized by the presence of both metabolic dysfunction and liver inflammation in individuals with other metabolic disorders suc...

aims to present the latest scientific advancements in the field of medicine in order to keep healthcare professionals updated on potential breakthroughs. In this article, we will analyze two recent publications related...

In a recent announcement, 89bio, Inc. revealed that it has approved the grant of non-qualified stock options to two new employees as part of its ongoing efforts to attract top talent and drive growth in the development...

SAN FRANCISCO, Dec. 06, 2023 - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic disease treatments, has announced its intention to conduct an underwritten publ...